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To test whether high circulating insulin concentrations influence the transport of β-alanine into skeletal 29 
muscle at either saturating or sub-saturating β-alanine concentrations, we conducted two experiments 30 
whereby β-alanine and insulin concentrations were controlled. Experiment 1: 12 men received 31 
supraphysiological amounts of β-alanine intravenously (0.11g·kg·min-1 for 150min), with or without insulin 32 
infusion. β-alanine and carnosine were measured in muscle before and 30 min after infusion. Blood samples 33 
were taken throughout the infusion protocol for plasma insulin and β-alanine analyses. β-alanine content in 34 
24-h urine was assessed. Experiment 2: 6 men ingested typical doses of β-alanine (10 mg·kg-1) before 35 
insulin infusion or no infusion. β-alanine was assessed in muscle before and 120 min following ingestion. In 36 
experiment 1, no differences between conditions were shown for plasma β-alanine, muscle β-alanine, 37 
muscle carnosine and urinary β-alanine concentrations (all p>0.05). In experiment 2, no differences between 38 
conditions were shown for plasma β-alanine or muscle β-alanine concentrations (all p>0.05). 39 
Hyperinsulinemia did not increase β-alanine uptake by skeletal muscle cells, neither when substrate 40 
concentrations exceed the Vmax of β-alanine transporter TauT, nor when it was below saturation. These 41 
results suggest that increasing insulin concentration is not necessary to maximise β-alanine transport into 42 
muscle following β-alanine intake. 43 
 44 














Carnosine (β-alanyl-L-histidine) is an intracellular dipeptide abundantly found in human skeletal 56 
muscle – content ranges from ~10 to ~40 mmol·kg-1 of dry muscle (40) – where it has important 57 
physiological roles, such as maintenance of acid-base homeostasis during high-intensity exercise (1, 4, 17), 58 
regulation of Ca2+ handling and sensitivity during muscle contraction (20, 26, 28), and scavenging of toxic 59 
products of lipid peroxidation (11). The rate-limiting factor for carnosine synthesis in skeletal muscle is the 60 
low availability of β-alanine (27), with β-alanine supplementation increasing muscle carnosine content by 61 
~40 to 100% (5, 40). 62 
Although β-alanine supplementation is the most effective known strategy to increase muscle 63 
carnosine content, previous studies showed that only ~6% of the total dose is used to synthesize carnosine in 64 
the skeletal muscle (9, 40). Despite the low efficiency in the use of β-alanine for carnosine synthesis, there is 65 
evidence to suggest that this can be improved when circulating insulin levels are elevated (42). A potential 66 
explanation for the enhanced carnosine synthesis is a putative increase in the efficiency of β-alanine 67 
transport into skeletal muscle.  68 
β-Alanine is thought to be transported into skeletal muscle cells via two different systems: 1) a 69 
saturable process undertaken by TauT (Taurine transporter - SLC6A6), which is a  Na+ and Cl- dependent 70 
transmembane transporter driven by transmembrane Na+ flux (30) whose Km (determined in primary cell 71 
culture of embryonic chick pectoral muscle) is ~40 µmol·L-1 (6); and 2) by PAT1 (SLC36A1),  which is a 72 
Na+-independent, H+-dependent transporter, whose activity is stimulated by the Na+/H+ exchanger (Km for a 73 
β-dipeptidemimetic is ~40 mmol·L-1) (22).         74 
 The Na+/K+/ATPase pump, Na+ influx and Na+/H+ exchanger are stimulated by insulin (13, 32, 39, 75 
44), although the stimulating effect appears to be tissue-specific (34). The transport of other small nitrogen-76 
containing molecules (i.e., creatine and carnitine) that, like β-alanine, are transported into skeletal muscle 77 
cells through Na+ flux driven mechanisms, is increased by elevated insulin concentrations (41, 43). Such an 78 
improvement in transport efficiency mediated by insulin may occur either via reduced Km (14) or increased 79 
Vmax (34). Due to the similarity in transport mechanisms between β-alanine, creatine and carnitine, it has 80 
been postulated that β-alanine transport into skeletal muscle could be further stimulated by hyperinsulinemia 81 
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(42).             82 
 Chronic supplementation of carnitine in combination with high loads of high glycemic-index 83 
carbohydrates increased muscle carnitine retention (43), whilst hyperinsulinemia also stimulates creatine 84 
transport into skeletal muscle (41). As yet, however, no study has directly examined the influence of insulin 85 
on β-alanine transport into skeletal muscle, although Stegen et al. (42) showed that ingesting β-alanine along 86 
with meals over a period of 46 days (3.2 g·d-1 split into 4 daily doses of 800 mg) resulted in superior 87 
carnosine accretion in the m. soleus in comparison with the group that ingested β-alanine in between meals 88 
(i.e., low insulin condition). These data led to authors to speculate that an elevation in insulin concentrations 89 
induced by meal ingestion could mediate intramuscular β-alanine/carnosine accumulation (42), although 90 
they did not show the same effect in a different muscle (m. gastrocnemius) in the same study, causing 91 
uncertainty as to whether insulin truly enhaces β-alanine uptake. To test the hypothesis that insulin levels 92 
influence β-alanine transport into skeletal muscle, we conducted two human studies using the 93 
hyperinsulinemic-euglycemic clamp technique, whereby both β-alanine and insulin concentrations were 94 




Ethical Approval 99 
 100 
The study was approved by the Ethics Committee of the School of Medicine of the University of Sao 101 
Paulo (#1185971) and complies with the standards established by the Declaration of Helsinki.  102 
 103 
Experiments 104 
In experiment 1, β-alanine was intravenously infused to reach supraphysiological concentrations of 105 
β-alanine in plasma to test whether insulin could stimulate β-alanine uptake when TauT was saturated. In 106 
order to confirm whether insulin could stimulate β-alanine uptake when both β-alanine transporters were not 107 
saturated, we then performed experiment 2, in which typical doses of β-alanine were ingested to reach 108 
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physiological concentrations of β-alanine in plasma, allowing us to better assess the effects of insulin on the 109 
Km of the transporters.  110 
 111 
Experiment 1: β-alanine infusion to reach saturating concentrations 112 
 113 
Participants 114 
Physically active male omnivores aged 18 to 35 years were eligible. Exclusion criteria were: use of 115 
dietary supplements containing β-alanine in the past 6 months, diagnosis of type I or type II diabetes 116 
mellitus, diagnosis of glucose intolerance, and the use of drugs known to interfere with insulin sensitivity or 117 
insulin secretion. We determined a priori that a sample size of 6 participants would be sufficient to detect a 118 
significant effect (alpha=0.05; 1-beta=0.8) of insulin on muscle β-alanine content, assuming an effect size > 119 
0.8 in a within-subject, repeated measures model (G*Power 3.1.9.2). Forty-eight individuals were screened 120 
for eligibility, 24 of whom met all criteria. Fourteen of these agreed to participate in the study. Two 121 
individuals did not complete the study as they were unwilling to undertake muscle biopsies. Thus, 12 122 
participants completed the entire study (age: 27±5 years, body mass: 79.6±7.4 kg, height: 1.80±0.06 m, 123 
habitual β-alanine intake in diet: 482±377 mg·day-1). 124 
 125 
Experimental design 126 
This was a counterbalanced, crossover study. Participants attended the laboratory on two different 127 
days, at least 10 weeks apart (i.e., sufficient time to allow complete washout of the β-alanine infused), for 128 
the main trials. On each trial, β-alanine was intravenously infused for 150 min with circulating insulin 129 
concentrations being kept high in one trial (HI), and low in the other trial (LI). Neither the researchers nor 130 
the participants were blinded to the conditions, due to the required experimental set-up, although all samples 131 
were analysed blinded to the condition by the use of unique identifying codes. Skeletal muscle samples were 132 
collected before and 30 min after the infusion period for the determination of muscle β-alanine and 133 
carnosine concentrations. Blood samples were collected before, throughout and after the infusion period for 134 
the analyses of plasma insulin, glucose and β-alanine. A midstream urine sample was collected before the 135 
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infusion period, and a 24 h total urine collection was carried out starting from the first urination after the 136 
beginning of the infusion period and ending 24 hours after the first urination.  137 
 138 
Main trials 139 
Participants arrived at the laboratory following a 12 h overnight fast, having not consumed any meat, 140 
fish or poultry for the last 24 h. On the first day, body mass and height were measured to calculate body 141 
surface area, a required parameter for calculating insulin and glucose infusion rates. Prior to infusion, the 142 
participants were asked to void their bladders and to collect a midstream urine sample, which was stored at -143 
80°C for further β-alanine analysis. Participants were then accommodated in a hospital bed for the insertion 144 
of cannulas. In the HI trial, two cannulas were inserted into different right arm veins for the infusion of 145 
insulin and β-alanine, whereas two cannulas were inserted into different veins of the left arm for glucose 146 
infusion and blood collection. In the LI trial, only β-alanine was infused; therefore, only one cannula was 147 
inserted into the right arm for the infusion of β-alanine and one cannula in the left arm for blood collection. 148 
The blood collection system was kept patent with the infusion of a saline solution, and a 55o C hand-149 
warming blanket was placed on the left arm for venous blood arterialization (23). 150 
After cannula insertion, a muscle sample was taken from the m. vastus lateralis by means of 151 
percutaneous needle muscle biopsy for β-alanine and carnosine determination. Following the biopsy, β-152 
alanine was infused with/without insulin and glucose for 150 min, a sufficient amount of time for tissue 153 
uptake of β-alanine (27). Blood samples were taken for β-alanine and insulin analyses at the following time 154 
points: before, 10, 30, 60, 90, 120, and 150 min after the beginning of the infusion, and 30 min after the end 155 
of the infusion. Subjective assessment of paraesthesia was performed using a 0-to-3-point scale at the same 156 
time points. A post-infusion muscle biopsy was performed 30 min after the end of the infusion, in order to 157 
allow time for the infused β-alanine to be incorporated into bodily tissues. In the HI trial, insulin and glucose 158 
infusion were maintained for 30 min after the end of β-alanine infusion, in order to allow insulin to play its 159 
putative role to stimulate β-alanine uptake by the skeletal muscle.     160 
Upon leaving the laboratory, all participants received a container and were requested to collect urine 161 
during the next 24 h and not to consume any type of meat during this period, with compliance being verbally 162 
Downloaded from journals.physiology.org/journal/ajpcell at Univ Col London (144.082.238.225) on March 18, 2020.
7 
 
confirmed with all participants. On the next day, total urine volume was measured with the aid of glass 163 
measuring cylinders, the urine was homogenized and two 50 mL-aliquots were stored at -80o C until 164 




Insulin and glucose infusion 169 
Insulin and glucose were only infused in the HI trials, following the same procedures described by 170 
DeFronzo et al. (16) for the hyperinsulinemic-euglycemic clamp. Insulin and glucose infusion rates were 171 
calculated according to individual body surface area. Insulin was then infused at a constant rate of 172 
40mU·m2·min-1 to reach the target concentration of ~100µU·mL-1.  The infusion of 10% glucose started 173 
concomitantly with insulin infusion and was adjusted every 5 min to maintain blood glucose concentrations 174 




β-alanine infusion 179 
Commercially available β-alanine in powder form (>99% purity) was obtained from Sigma-Aldrich. 180 
Before commencing the study, β-alanine powder was sterilized with gamma radiation (60Co multipurpose 181 
irradiator - IPEN-CNEN/SP, Brazil) in order to ensure safety and functionality of β-alanine, as previously 182 
described (24). Sterile β-alanine was diluted in 500 mL of saline solution. Infusion rates of β-alanine were 183 
adjusted according to individual’s body mass, totalling 0.11 g·kg-1 during the entire 150 min infusion period. 184 
This was determined to be the near the maximal tolerable amount for infusion within 150 min during pilot 185 
testing. These high amounts were chosen to elicit supraphysiological β-alanine concentrations and saturate 186 
TauT, so we could test whether insulin stimulates β-alanine transport when its concentration is above the 187 
Vmax of TauT. β-alanine was infused at increasingly high rates during the first 20 min; infusion rates were 188 
increased every 5 min, as follows: 0.25, 0.50, 0.60 and 0.70 mg·kg-1·min-1 until they reached 0.80 mg·kg-189 
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1·min-1, which was kept constant for the remaining 130 min of infusion. Mean±SD β-alanine infusion rate 190 
was 60.6 ± 5.7 mg·min-1, and mean±SD total β-alanine infusion was 9.16 ± 0.78 g. 191 
 192 
Muscle biopsies 193 
Muscle samples (~70-150 mg) were collected from the middle portion of the vastus lateralis using 194 
the percutaneous needle biopsy technique (8) with suction (37). A 1-cm wide incision was made on the skin 195 
and fascia under local anesthesia (3 mL, 2% xylocaine) to make muscle tissue acessible. Post-infusion 196 
biopsies were performed in an adjacent location, ~1 cm apart in the lateral axis, and at a similar depth. 197 
Immediately after sample collection, blood, fat and connective tissue were removed. The samples were snap 198 




Sample collection and insulin determination 203 
Blood samples were collected in vacuum tubes (BD Vacutainer®) containing clot activator for 204 
plasma insulin determination, and K-EDTA for β-alanine determination. The samples for insulin were kept 205 
at room temperature until the end of the infusion procedure and then immediately taken to the Central 206 
Laboratory of the Clinical Hospital for processing and analysis using an immunofluorometric method. The 207 
samples for β-alanine determination were immediately centrifuged, and plasma was stored at -80°C for 208 
further analysis. 209 
 210 
Determination of β-alanine in plasma, muscle and urine, and carnosine in muscle by HPLC-ESI+-211 
MS/MS 212 
Twenty micro-liters of plasma were extracted in 980 μLof cold extraction buffer 213 
(methanol:acetonitrile:water 5:3:2 v/v). The extracts were then vortexed for 10 min (30-s bursts interspersed 214 
with 30s periods on ice) and centrifuged at 10,000g for 10 min at 4°C (36). The supernatants were 215 
subsequently submitted to analysis. 216 
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Approximately 3-4 mg of lyophilized muscle was powdered and deproteinized with 0.5M HClO4, 217 
vortexed for 15 min and centrifuged at 5,000 g at 4°C for 3 min (19). Samples were neutralized with 2.1M 218 
KHCO3, centrifuged at 5,000 g at 4°C for 3 min, and the supernatant stored at -80°C for further analysis. 219 
Pure urine samples were diluted in water (1:100 v/v) for subsequent analysis. Plasma, muscle and 220 
urine samples and standards were quantified in duplicate and analyzed by on-line HPLC-ESI+-MS/MS using 221 
CAR-d4 as internal standard (11). Analysis was conducted in the positive mode and detection was realized 222 
on a triple quadrupole mass spectrometer API 6500 (Sciex, Washington D.C, WA), using selected reaction 223 
monitoring (SRM). For sample injection and cleanup, we used an Agilent HPLC system (Agilent 224 
Technologies, Santa Clara, CA) equipped with an autosampler (1200 High performance), a column oven set 225 
at 45°C (1200 G1216B), an automated high pressure flow switching valve, a 1200 Binary Pump SL and a 226 
Shimadzu10-AVp Isocratic Pump (Shimadzu, Tokyo, Japan) on two columns: Kinetex C18 column 227 
(100×4.6mm; particle diameter of 2.6 μm (Phenomenex, Torrance, CA) and Kinetex C18 column 228 
(100×2.1mm; particle diameter 2.6 μm (Phenomenex, Torrance, CA). The mobile phase consisted of 5mM 229 
ammonium acetate pH 5.5 (A) and acetonitrile (≥99.9% HPLC grade, Sigma-Aldrich) (B). Both solutions 230 
were filtered through a 0.22 μm PVDF membrane (Millipore, Bedford, MA). The separation condition was 231 
as follows: from 0 to 6 min, 10% acetonitrile and 150 μl/min; from 6 to 10 min, 10–90% acetonitrile and 232 
150–300 μL/min; from 10 to 15 min, 90% acetonitrile and 300 μL/min; from 15 to 20 min, 90–10% 233 
acetonitrile and 300–150 μL/min allowing the first column to re-equilibrate until 30 min. A high-pressure 234 
flow switching valve composed of 2-positions and 6-ports was inserted between the two columns. The 235 
eluent from the first column was discarded by the valve up to the 3rd min of the run while keeping the 236 
second column supplied with a solution of water:acetonitrile (9:1, v/v) at a constant flow rate of 100 μL·min-237 
1 (Shimadzu 10-AVp Isocratic Pump). After 3 min of the run, the valve switched position and the eluent of 238 
the first column entered the second column. Then, the samples were injected into the mass spectrometer. 239 
The valve returned to the starting position after 14 min of the run and both columns were rebalanced. 240 
Electrospray ionization (ESI) in the positive mode was used, and detection was made using selected 241 
reaction monitoring (SRM) on a triple quadrupole mass spectrometer. The Turbo Ionspray Voltage was kept 242 
at 5500 V, curtain gas at 15 psi and the nebulizer and auxiliary gas at 50 psi. The temperature was set to 243 
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500°C, and the pressure of nitrogen in the collision cell was adjusted to high. The signal to noise ratio (S/N) 244 
of  ≥7 was used as the quantification criteria. S/N transitions for β-alanine, carnosine and CARd4 were 245 
monitored using a dwell time of 150 ms. 246 
β-alanine was not derivatized prior to analysis and the SRM transitions monitored were m/z 90→72 247 
(quantification transition), m/z 90→45 and m/z 90→30 (confirmation transition). The quantification 248 
transition m/z 90→72 is unique to β-alanine and can be used to differentiate the α- from the β-isomer (38). 249 
SRM transitions monitored for carnosine were m/z 227→110 (quantification transition) and m/z 227→210 250 
(confirmation transition). SRM transitions monitored for CARd4 were m/z 231→110 (quantification 251 
transition) and m/z 231→214 (confirmation transition). Representative chromatograms of plasma, urine and 252 
muscle samples are displayed in figure 2. 253 
 254 
Paraesthesia evaluation scale 255 
Because paraesthesia is a major side-effect of elevated plasma β-alanine concentrations (27), we 256 
monitored its occurence and intensity as a safety measure at the following time points: before infusion, 10, 257 
30, 60, 90, 120, 150 min following the start of infusion, and 30 after the end of infusion, using a 0-3 scale 258 
adapted from Lingjaerde et al. (33), where zero means "I don`t feel paraesthesia or I'm not sure what I feel”, 259 
one means "I feel slight paraesthesia that hardly bothers me”, two means "I feel moderate paraesthesia, 260 
which clearly bothers me", and three means “I feel intense paraesthesia, which bothers me a lot". 261 
 262 
Dietary β-alanine intake assessment 263 
Participants completed food diaries on 3 non-consecutive days (two weekdays and one weekend day) 264 
following the instructions of a registered nutritionist. β-alanine intake through consumption of fish, poultry 265 
and meat was estimated from the data of Jones et al. (31). 266 
 267 
 268 
Experiment 2: β-alanine ingestion to reach sub-saturating concentrations 269 
 270 




Six male omnivores (age: 25±3 years, body mass: 78.7±10.1 kg, height: 1.76±0.03 m, habitual β-272 
alanine intake in diet: 636±196 mg·day-1) were recruited to participate in this experiment, all of whom 273 
completed the entire study protocol. One of the participants also participated in experiment 1. Inclusion and 274 
exclusion criteria were the same of the experiment 1, as detailed above.  275 
 276 
Experimental design 277 
The experimental design is essentially the same as that used in the experiment 1, except for the oral 278 
ingestion of β-alanine (rather than infusion), the smaller amount of β-alanine provided, the shorter washout 279 
period, the shorter time-course, and the ommision of urine collection. The shorter washout period is justified 280 
by the low total β-alanine administration, which is assumed to have little or no noticieable impact on muscle 281 
carnosine concentrations. The time-course was defined based on the pharmacokinetics of β-alanine 282 
appearance and disappearance from plasma after ingestion (Harris et al., 2006). In this counterbalanced, 283 
crossover study, participants attended the laboratory on two different days, 7 days apart (i.e., sufficient time 284 
to allow complete washout of the β-alanine ingested). On each trial, 10 mg·kg-1 BM of pure powdered β-285 
alanine was ingested, dissolved in 200 mL of tap water. Upon ingestion, circulating insulin concentrations 286 
was kept high in one trial (HI), and low in the other trial (LI) for 120 min, with trial order being 287 
counterbalanced. Neither the researchers nor the participants were blinded to the conditions, due to the 288 
required experimental set-up, although all samples were analysed blinded to the condition by the use of 289 
unique identifying codes. Skeletal muscle samples were collected before and after 120 min of insulin 290 
infusion (or no infusion) following β-alanine ingestion. Blood samples were collected before, throughout 291 
and after the infusion period for the analyses of plasma insulin, glucose and β-alanine. Figure 1 (right panel) 292 
illustrates the experimental design. 293 
All procedures of the main trials, including blood collection, muscle biopsy, hyperinsulinemic-294 
euglycemic clamp, sample processing and analyses were identical to those described in the experiment 1. 295 
 296 
Statistical Analysis 297 
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 Mixed model (proc mixed, SAS v. 9.3) procedure was used to compare muscle β-alanine and 298 
carnosine content between conditions, as well as plasma β-alanine and insulin concentrations and 299 
paraesthesia ratings between conditions. Condition (HI and LI) and time were included as fixed factors and 300 
participants were included as random factors. Tukey-Kramer adjustment for multiple comparisons was 301 
performed whenever a significant F-value was obtained. The area under the curve (AUC) was calculated 302 
using the linear trapezoidal method. Paired t-tests were used to compare the AUC of plasma insulin and 303 
plasma β-alanine, and β-alanine in the 24-h urine samples. Statistical significance was accepted at p≤0.05. 304 




Experiment 1: Effect of insulin on β-alanine transport at saturating concentrations 309 
 310 
Plasma insulin 311 
Insulin concentrations were significantly higher in HI than in LI (condition-by-time interaction: 312 
p<0.0001) at all time-points (pairwise analyses: all p<0.0001), with the exception of baseline (p=0.8) 313 
(Figure 3, panel A). A significantly higher insulin AUC was shown in HI than in LI (p<0.0001; 314 
95%CI=8596-13112). These data confirm that the clamp technique was able to sustain physiological 315 
hypersulinemia throughout the entire procedure. 316 
  317 
Plasma β-alanine 318 
Plasma β-alanine concentrations increased following β-alanine infusion and remained elevated 319 
throughout the infusion period (main effect of time: p=0.0001). Although a significant condition-by-time 320 
interaction was shown (p=0.03), no significant differences between LI and HI were shown at any time point 321 
(pairwise comparisons: all p>0.05). Similarly, no significant differences between conditions were shown for 322 
the area under the plasma β-alanine curve (p=0.34; 95%CI=-177130 – 67097) (figure 4, panel A). 323 
 324 
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Muscle β-alanine 325 
β-alanine infusion resulted in a ~2.5 to 3.0-fold increase in muscle β-alanine content (main effect of 326 
time: p<0.0001), with no significant differences between HI and LI conditions (condition-by-time 327 
interaction: p=0.85) (figure 4, panel B). 328 
 329 
Muscle carnosine 330 
Muscle carnosine concentrations did not significantly change following the infusion of β-alanine, 331 
irrespective of condition (main effect of time: p=0.08; main effect of condition: p=0.75; condition-by-time 332 
interaction: p=0.18) (figure 4, panel C). 333 
 334 
 335 
 Urinary β-alanine  336 
β-alanine concentrations were below the limit of detection in all midstream urine samples collected 337 
before infusion in both trials (therefore, data are not shown). Large amounts of β-alanine were, however, 338 
detected in the 24 h urine samples following infusion, but no significant differences between conditions 339 
were shown (p=0.95; 95%CI=-3.1 – -2.9) (figure 4, panel D). 340 
 341 
  Paraesthesia 342 
A significant main effect of time (p<0.0001) was shown for self-reported ratings of paraesthesia 343 
throughout the main trials, indicating that β-alanine infusion elicited some degree of paraesthesia. No 344 
significant differences between conditions were, however, shown (main effect of condition: p=0.68; 345 
condition-by-time interaction: p=0.06) (figure 5). 346 
 347 
Experiment 2: Effect of insulin on β-alanine transport at sub-saturating concentrations 348 
 349 
Plasma insulin 350 
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Insulin concentrations were significantly higher in HI than in LI (condition-by-time interaction: 351 
p<0.0001) at all time-points (pairwise analyses: all p<0.001), except at baseline (p>0.999) (Figure 3, panel 352 
B). A significantly higher AUC was shown in HI than in LI (p=0.004; 95%CI=-17260 – -6214). These data 353 




Plasma β-alanine 358 
Plasma β-alanine concentrations rapidly increased following β-alanine ingestion and tended to return 359 
to pre-ingestion levels towards to the end of the 120 min period (main effect of time: p<0.0001). No 360 
differences were shown between LI and HI (condition-by-time interaction: p=0.58; pairwise analyses: all 361 
p>0.05) and there were no significant differences between conditions for the β-alanine AUC (p=0.23; 95% 362 
CI=-935 – 3070) (figure 6, panel A). 363 
 364 
 365 
Muscle β-alanine 366 
β-alanine ingestion resulted in a ~1.5-fold increase in muscle β-alanine content (main effect of time: 367 
p=0.0003), with no significant differences between HI and LI (main effect of condition: p=0.37; condition-368 
by-time interaction: p=0.32) (figure 6, panel B). 369 
 370 
Discussion 371 
This study aimed to test the hypothesis that hyperinsulinemia could stimulate β-alanine transport to 372 
skeletal muscle. Our experimental setup allowed tight control over blood insulin concentrations (figure 3) 373 
while testing different concentrations of plasma β-alanine. Our findings provide compelling evidence that 374 
hyperinsulinemia does not increase β-alanine uptake by muscle cells, neither when substrate concentrations 375 
exceeded the Vmax of TauT, nor when it was at a level below the saturation of β-alanine transporters. β-376 
alanine transport across membranes can occur through three different protein transporters, namely TauT 377 
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(SLC6A6), PAT1 (SLC36A1) and ATB0,+ (SLC6A14) (3). However, only the genes encoding TauT and 378 
PAT1 have been shown to be expressed in human skeletal muscle (21), with only the former being 379 
characterised in terms of physical-chemical properties in skeletal muscle cells (7). Thus, very little is 380 
currently known about their specific mechanisms in human skeletal muscle.  381 
TauT is a high-affinity, low-capacity transporter that carries β-alanine and taurine across membranes 382 
in a Na+ and Cl- dependent manner in a ratio of 1:1:2 (3, 30). Due to this ionic dependency, TauT operates as 383 
a secondary active transport system, whereby the transporting energy is obtained through an electrochemical 384 
gradient of Na+, which is maintained by the activity of the Na+/K+/ATPase pump (25). PAT1 is a Na+-385 
independent, H+-dependent, low-affinity, high-capacity transport system of zwitterionic amino acids, 386 
including β-alanine, taurine and GABA (10, 12). Although the PAT1 transporter is not dependent on Na+, 387 
evidence indicates that Na+ can stimulate PAT1 activity (2). This suggests that optimal PAT1 activity is 388 
coupled to the activity of the Na+/H+ exchanger, since the Na+/H+ exchanger increases the H+ gradient across 389 
the membrane, thereby increasing the driving force for PAT1 (29). 390 
Studies using the m. sartorius of frog (35) and the m. soleus of rat (14) suggest that insulin stimulates 391 
Na+/K+/ATPase pump activity by increasing intracellular Na+ affinity. In human fibroblasts, Longo (34) 392 
showed that insulin increased pump activity and Na+/K+/Cl- co-transport by increasing the Vmax of the 393 
transporters without affecting their Km. Because the activity of the Na+/K+/ATPase pump (13, 39, 44) and 394 
the Na+/H+ exchanger are stimulated by insulin (32), it has been hypothesised that hyperinsulinemia could 395 
stimulate the transport of β-alanine into human skeletal muscle, ultimately leading to increased muscle 396 
carnosine accrual in response to β-alanine supplementation (42). From an applied standpoint, higher 397 
amounts of β-alanine could be transported into skeletal muscle if the Vmax of TauT were increased, which 398 
could potentially increase the β-alanine-to-carnosine conversion inside the muscle cells over a β-alanine 399 
supplementation period. This, at least in theory, would mean that either a) the individual could attain a 400 
greater increase in muscle carnosine stores during any given supplementation period (optimising its effects) 401 
or b) the individual could reduce the required supplementation time (making β-alanine supplementation 402 
more user friendly). 403 
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Mechanisms of transport can be enhanced by increasing either the maximum velocity of the 404 
transporter (Vmax) or the affinity between the transporter and its substrate (decreased Km). Increased transport 405 
capacity is observable when substrate concentrations are above the saturation limit of the transporter, 406 
whereas increased affinity is observable when substrate concentrations are below transporter saturation. In 407 
our first experiment, the rate of β-alanine infusion was virtually the maximum tolerable, considering the 408 
degree of paraesthesia elicited. The elevation in plasma β-alanine concentrations (~3000-4000 µmol·L-1) 409 
have certainly exceeded the maximum capacity of TauT (whose Km is reported to be ~100-fold lower), but 410 
were probably below the saturation of PAT1 (whose Km for a β-dipeptidemimetic is ~10-fold higher) (22). 411 
Thus, it seems impossible to create an experimental condition that would allow the determination of whether 412 
insulin could further increase the already high capacity of the PAT1 transporter. Attaining larger 413 
concentrations of β-alanine in plasma is too far from any physiological condition and, therefore, of little 414 
practical relevance. Since we did not show any evidence of the stimulatory effect of insulin on β-alanine 415 
transport in experiment 1, it seems safe to conclude that insulin does not increase the Vmax of TauT, or the Km 416 
of PAT1.   417 
Although experiment 1 quite conclusively showed no effect of insulin on the Km of PAT1 or the Vmax 418 
of TauT, it does not rule out the possibility of insulin enhancing transport when β-alanine concentrations are 419 
below the saturation of TauT. The hypothesis in this case was that insulin could increase the affinity 420 
between β-alanine and TauT, thereby decreasing its Km. To test this remaining hypothesis, we then 421 
conducted experiment 2, where the experimental approach was essentially the same, but the β-alanine 422 
concentrations were much lower. This was attained using a typical dose of orally ingested β-alanine; one 423 
advantadge of this design is to test the stimulatory effects of insulin under conditions that are similar to 424 
typical physiological conditions. The results of experiment 2 further confirmed the lack of an effect of 425 
insulin on β-alanine transport. 426 
Collectively, the results of this in vivo human study suggest that insulin does not decrease the Km of 427 
PAT1, increase the Vmax of TauT, or decrease the Km of TauT. Although the effects on the Vmax of PAT1 428 
remain untested, the physiological plausibility of such a high β-alanine concentration in plasma is virtually 429 
non-existent, so that it has very little practical relevance. The lack of effects on PAT1 transport activity can 430 
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be explained based upon the fact that Na+ increases PAT1 activity via an increased proton gradient only 431 
when intracellular pH is acidic, ranging from 5.5 to 6.0 (10, 12, 15, 29). Since these conditions are one order 432 
of magnitude away from the physiological pH of resting muscle (pH ~7.0), we speculate that any putative 433 
effect of insulin on the Na+/H+ exchanger, and ultimately on PAT1 activity, would not be observable under 434 
physiological conditions. Although it is difficult to provide a clear explanation for the lack of effects of 435 
insulin on TauT activity, we can only speculate that TauT could be less sensitive to increases in the 436 
intramembrane Na+ gradient, brought about by increased Na+/K+/ATPase activity, than other transporters, 437 
which might be a consequence of the high-affinity and the rapid saturation of TauT. Alternatively, any 438 
effects of insulin on TauT activity at the molecular level could be so minor that they do not translate into 439 
physiological effects that are observable in whole-body fully integrated systems. Therefore, despite the use 440 
of highly sensitive methods in this study, no stimulatory effects of insulin were detected, meaning that they 441 
are either non-existent or too small to be of any physiological significance.  442 
Our findings contradict those by Stegen et al. (42), who showed that supplementation of 3.2 g·d-1 of 443 
β-alanine (4 daily doses of 800 mg) for 46 days significantly increased muscle carnosine concentration in the 444 
group that supplemented β-alanine along with meals when compared to the group that consumed β-alanine 445 
in between meals. Although this study was not designed to assess β-alanine transport or the effects of insulin 446 
directly, the increased muscle carnosine accretion led to the suggestion that insulin could stimulate β-alanine 447 
transport into skeletal muscle. This effect was, however, only shown in the m. soleus and not in the m. 448 
gastrocnemius, casting some doubt upon this purported effect. The current study provides clear experimental 449 
support to show that there is no stimulatory effect of insulin on β-alanine transport into skeletal muscle. One 450 
alternative explanation for the findings by Stegen et al. (41) is that, instead of an effect of hyperinsulinemia,  451 
food intake might have increased the availability of substrates for the enzymes that degrade β-alanine (4-452 
aminobutyrate-2-oxoglutarate transaminase and alanine-glyoxylate transaminase), which would have 453 
increased the competition for the binding site of the enzymes, thereby resulting in greater β-alanine 454 
availability for synthesising carnosine. This hypothesis, however, remains highly speculative and requires 455 
experimental confirmation.  456 
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It is interesting to note that a large increase in muscle β-alanine was shown 2-3 hours following β-457 
alanine administration in both experiments. Although this rapid increase points to the efficiency of the 458 
transport systems, the administration of ~10-fold larger doses in experiment 1 vs. experiment 2 resulted in 459 
muscle β-alanine accretion of comparable magnitudes, thereby suggesting a saturation in β-alanine transport. 460 
The excess of β-alanine that does not enter the muscle seems to be, at least in part, eliminated in the urine, as 461 
indicated by the high amount (~50% of the total administered) of β-alanine appearing in the urine in 462 
experiment 1. In the experiment 2, we did not collect 24-h urine samples to measure β-alanine losses, but 463 
Harris et al. (2006) (27) showed a much smaller (~3% of total administered) β-alanine loss in urine with the 464 
same dose (800 mg) of β-alanine (taken orally) as we used in experiment 2. These results appear to be 465 
consistent with a high-affinity, low-capacity transporting system, and might suggest that TauT (high-466 
affinity, low-capacity) is the major β-alanine transporter in the skeletal muscle whilst PAT1 (low-affinity, 467 
high-capacity) might play a secondary role. Further studies are needed to precisely characterise the specific 468 
roles of TauT and PAT1 on muscle β-alanine uptake. 469 
The saturation of β-alanine transport appears to occur at plasma concentrations close to those elicited 470 
by typical supplemental doses of β-alanine, which indicates that the ingestion of larger doses will probably 471 
not result in substantial increases in β-alanine uptake by the skeletal muscle but, instead, will likely result in 472 
larger losses in urine. The rapid and marked increase in muscle β-alanine in only 2-3 hours 473 
following/alongside β-alanine administration constrasts with the lack of increase in muscle carnosine in the 474 
same period.  475 
One possible explanation for the mismatch between β-alanine transport (rapid) and carnosine 476 
synthesis (slow) could be related to the β-alanine transport systems, which, despite being saturable, appear to 477 
be relatively more efficient than the carnosine synthase enzyme. This could suggest that β-alanine transport 478 
is not the limiting factor for carnosine synthesis, at least when ample β-alanine is available. Under these 479 
circumstances, the activity of carnosine synthase, rather than β-alanine availability, could be limiting for 480 
carnosine synthesis. This notion is supported by a cell culture study where an excess of β-alanine availability 481 
led to the saturation of carnosine synthase, making it the rate-limiting factor for β-alanine-to-carnosine 482 
conversion (6), and by chronic β-alanine supplementation studies showing that carnosine saturation may not 483 
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occur even after 24 weeks of supplementation (40). This is also in line with pharmacokinectic studies that 484 
showed elevated whole-body retention rates (~97%) when typical doses of β-alanine were orally ingested, 485 
along with only minimal losses in urine (27), and with the low rate of β-alanine-to-carnosine conversion in 486 
the skeletal muscle (typically <6% of the total β-alanine ingested) (9, 40). This temporal mismatch would 487 
result in free β-alanine accumulation in muscle, which would fit with the findings of Blancquaert et al. (9) 488 
who showed that the excess of β-alanine becomes available to transaminases that degrade β-alanine in the 489 
muscle and liver, ultimately directing β-alanine towards oxidation (9). If the activity of carnosine synthase 490 
was the rate-limiting factor for carnosine synthesis when β-alanine is largely available in the skeletal muscle, 491 
it would be questionable whether increasing β-alanine uptake into skeletal muscle would result in more 492 
carnosine synthesis unless this were accompanied by an increase in the activity of carnosine synthase. If we 493 
assume this hypothesis to be correct, then it would make sense to find ways to increase carnosine synthase 494 
activity, rather than β-alanine availability, as a means to maximise carnosine accretion in the skeletal 495 
muscle. 496 
 On the other hand, the experimentally determined Km of carnosine synthase, which is 90 µmol·l-1 497 
(18) is far in excess of the muscle β-alanine concentrations (~5-8 µmol·l-1) attained following β-alanine 498 
administration in our study. This means that much larger β-alanine concentrations would be required to 499 
significantly elevate the activity of carnosine synthase, which somewhat contradicts the idea that further 500 
increased β-alanine availability is not limiting for carnosine synthesis when β-alanine is already elevated. As 501 
such, we cannot rule out the possibility that other strategies to increase β-alanine transport to skeletal muscle 502 
could result in further increased muscle carnosine synthesis. Our study clearly demonstrates that 503 
hyperinsulinemia is not one of these strategies. It also seems that increasing plasma β-alanine concentrations 504 
above those already achieved with currently used supplemental doses have little potential to further enhance 505 
carnosine synthesis. Future studies could, however, focus upon other ways to maximise carnosine accretion 506 
and the molecular mechanisms underlying such effects should they exist.    507 
In conclusion, the present study showed that high insulin concentrations do not stimulate β-alanine 508 
transport into skeletal muscle, neither does it increase whole-body β-alanine retention. The lack of effect 509 
was demonstrated under both physiological and supraphysiological β-alanine concentrations, suggesting that 510 
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insulin has no physiologically relevant effect on any of the β-alanine transporters. From an applied 511 
perspective, our findings suggest that β-alanine ingestion does not need to be accompanied by a high-512 
carbohydrate meal; therefore, β-alanine supplementation strategies that manipulate insulin concentrations 513 
seem not to be required. 514 
 515 
 516 
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Figure 1. Experimental design and representation of the main trials in both experiments 682 
where supraphysiological β-alanine concentrations were attained with intravenous 683 
infusion (Experiment 1, left panel) and physiological concentrations were attained with 684 
the ingestion of typical doses of β-alanine (Experiment 2, right panel). HI=high insulin. 685 
 686 
Figure 2. Representative chromatograms displaying monitored transitions of β-alanine, 687 
carnosined4, and carnosine in plasma, urine and skeletal muscle extracts.  688 
 689 
Figure 3. Plasma insulin concentrations during 180 min of intravenous insulin infusion 690 
(HI) or basal fasting insulin (LI) in experiment 1 (panel A) and during the 120 min of 691 
insulin infusion or basal fasting in experiment 2 (panel B).  692 
AUC: area under the curve (p<0.0001). 693 
 694 
Figure 4. Panel A: Plasma β-alanine concentrations during the 180 min β-alanine 695 
infusion period in both high (HI) and low insulin (LI) conditions (left chart), and area 696 
under the β-alanine curve (AUC) in both conditions (right chart). No differences 697 
between LI and HI were shown at any time point (all p>0.05). Panels B and C: 698 
Intramuscular concentrations of β-alanine and carnosine in muscle extracts obtained 699 
before and after β-alanine infusion in both HI and LI conditions. Panel D: Total β-700 
alanine recovered in the 24-h urine samples collected after infusion in both HI and LI 701 
conditions. All results refer to data obtained in the experiment 1. 702 
p-values on panels B and C refer to condition-by-time interaction. 703 
Two participants were assessed per trial, meaning that a total of 12 independent 704 
experiments were conducted, totalising 24 observations. 705 





Figure 5. Subjective ratings of paraesthesia reported before and throughout β-alanine 708 
infusion in experiment 1. All participants reported no paraesthesia in experiment 2 at 709 
any time point following β-alanine ingestion (therefore, data are not shown). No 710 
significant differences between conditions were shown. 711 
 712 
Figure 6. Panel A: Plasma β-alanine concentrations during the 120 min after β-alanine 713 
ingestion in both high (HI) and low insulin (LI) conditions (left chart), and area under 714 
the β-alanine curve (AUC) in both conditions (right chart). No differences between LI 715 
and HI were shown at any time point (all p>0.05). Panel B: β-alanine concentrations 716 
measured in muscle extracts obtained before and after β-alanine ingestion in both HI 717 
and LI conditions. All results refer to data obtained in the experiment 2. 718 
p-values on panel B refer to condition-by-time interaction (above) and Tukey-Kraemer 719 
adjusted pairwise comparison vs. before ingestion. 720 
Two participants were assessed per trial, meaning that a total of 6 independent 721 
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